Clinical Trial Search

Primary: Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator) — 3; 3; 2; 1 Number of subjects with any symptom

Primary: Response Rate (RR) — 0; 0; 2; 15 Participants

Primary: Change From Baseline in the Area Under the Curve (AUC) of Breath CH4 Production at Day 7 — 99.2; 57.3; 72.7 hours*ppm

Primary: Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity — 0; 0; 0 Participants

Primary: Change From Study 1 (NCT02495623) Baseline in the Area Under the Curve (AUC) of Breath CH4 Production, Based on a 180-minute Lactulose Breath Test (LBT) at Day 56…

Primary: Percentage of QGE031 Participants With Clinically Important Improvement of <= -0.5 in the Asthma Control Questionnaire 7 (ACQ-7) Score Compared to Placebo — 63.16…

Primary: Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]) — -2.92; -10.76; -3.40 % Change…

Primary: Peak Melatonin Level — 405; 3999; 52 pg/ml — p=<0.001

Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 — 17.4; 13.6 percentage of participants

Primary: Percentage of Participants With Greater Decrease In Overall Target Plaque Severity Score (OTPSS): Ointment (2% Twice Daily), Vehicle — 54.1; 2.7 percenatge of…

Primary: Progression-free Survival — 5.6; 5.1 months

Primary: Atopic Dermatitis Severity Index (ADSI) Score at Baseline (Day 1) — 8.0; 8.3; 8.0; 8.4 units on a scale

Primary: Progression Free Survival — 2.07 months

Primary: Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks) — 23.8; 30; 13.0; 28.8 units on a scale

Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients